YAP1 and non-small cell lung carcinoma: Besides, YAP1 is overexpressed in NSCLC and the loss of YAP1 has potential as a clinical marker for predicting NE features (Ito et al., 2016), and YAP1, combined with ASCL1, NEUROD1, and POU2F3, can be used to define SCLC subtypes (Baine et al., 2020).